In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PharmAkea Therapeutics Inc.

www.pharmakea.com

Latest From PharmAkea Therapeutics Inc.

Celgene's Partnered Pipeline Delivers Successes And Setbacks

Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.

Deals Business Strategies

Deals Of The Week Keeps Tabs As Tax Trimming Fuels Deal-Making

As more biopharmaceutical companies become profitable and global, tax strategy becomes an increasingly important aspect of deal-making and intellectual property management. Deals of the Week looks at recent tax winners, new tax tactics and potential deal targets that are attractive in part because of their high – or low – tax rates.

BioPharmaceutical Deals

Biopharma Dealmaking Quarterly Statistics, Q4 2013

Biopharma financing totaled $6.4 billion, a 39% increase over Q3. Twenty-three M&As were completed with a combined potential value of $19.8 billion, and there were 103 biopharma alliances totaling $2.5 billion in potential pre-commercialization value, down 25% from the previous quarter.

BioPharmaceutical Deals

The A-List: The Trend-Shaping Series A Financings Of 2013

It’s the 10th anniversary of START-UP’s A-List, an analysis of the year’s Series A life science funding, and a highlight of the year’s most interesting new companies. Deal flow was up this year, as was the average disclosed amount of financing.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Musculoskeletal & Connective Tissue Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • PharmAria LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • PharmAkea Therapeutics Inc.
  • Senior Management
  • Robert F Williamson, III, CEO
    John Hutchinson, PhD, Pres.
    Jilly Evans, PhD, CSO
    Kevin Holme, PhD, COO
    Vanessa Jacoby, Exec. Dir., Fin.
  • Contact Info
  • PharmAkea Therapeutics Inc.
    12780 El Camino Real
    San Diego, CA 92103
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register